Compare RSG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RSG | REGN |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5B | 79.4B |
| IPO Year | 1998 | 1995 |
| Metric | RSG | REGN |
|---|---|---|
| Price | $219.50 | $779.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 23 |
| Target Price | $248.32 | ★ $812.57 |
| AVG Volume (30 Days) | ★ 1.4M | 732.6K |
| Earning Date | 05-20-2026 | 04-16-2026 |
| Dividend Yield | ★ 1.13% | 0.48% |
| EPS Growth | 5.55 | ★ 8.19 |
| EPS | 6.85 | ★ 41.48 |
| Revenue | ★ $19,027,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $5.49 | $11.69 |
| Revenue Next Year | $5.13 | $10.12 |
| P/E Ratio | $32.04 | ★ $18.80 |
| Revenue Growth | 3.31 | ★ 20.82 |
| 52 Week Low | $201.42 | $476.49 |
| 52 Week High | $258.75 | $821.11 |
| Indicator | RSG | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 53.11 |
| Support Level | $209.48 | $783.62 |
| Resistance Level | $224.61 | $815.00 |
| Average True Range (ATR) | 5.01 | 22.83 |
| MACD | -0.15 | 1.25 |
| Stochastic Oscillator | 57.44 | 58.08 |
Republic Services Group is the second-largest waste management company by revenue and provides integrated waste management services to residential, commercial, and industrial customers. With 208 active landfills, 248 transfer stations, and 75 recycling centers, Republic Services has reached $16 billion in annual revenue, focusing on recycling and environmental solutions. The company reports in three segments based on the Western United States (Group 1), Eastern United States (Group 2), and Environmental Solutions across North America (Group 3). Eighty-nine percent of total revenue comes from recycling and waste, with the remaining 11% from Environmental Solutions.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).